A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
A phase 1/2 trial of IBI354 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
Overview
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05636215 by Innovent Biologics (Suzhou) Co. Ltd., with 368 participants planned, started 2023-04-04 and due to reach its primary completion in 2025-04-30. Interventions recorded: IBI354.
Similar pages
not linked directly; found by shared links- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAuger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.